ASP Isotopes Inc. Forecasted to Post FY2025 Earnings of ($0.07) Per Share (NASDAQ:ASPI)

ASP Isotopes Inc. (NASDAQ:ASPI) – Research analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for ASP Isotopes in a note issued to investors on Wednesday, April 17th. HC Wainwright analyst H. Ihle expects that the company will earn ($0.07) per share for the year. HC Wainwright currently has a “Buy” rating and a $5.50 price target on the stock. The consensus estimate for ASP Isotopes’ current full-year earnings is $0.07 per share.

ASP Isotopes Trading Down 3.8 %

Shares of ASP Isotopes stock opened at $3.04 on Thursday. The firm has a market capitalization of $148.72 million, a PE ratio of -6.20 and a beta of 5.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.85 and a quick ratio of 1.85. The company’s fifty day moving average price is $3.67 and its two-hundred day moving average price is $2.38. ASP Isotopes has a 52-week low of $0.28 and a 52-week high of $4.97.

Institutional Investors Weigh In On ASP Isotopes

Several institutional investors and hedge funds have recently made changes to their positions in ASPI. Millennium Management LLC acquired a new position in ASP Isotopes during the 4th quarter worth about $49,000. Armistice Capital LLC acquired a new position in ASP Isotopes during the 1st quarter valued at about $2,702,000. Renaissance Technologies LLC bought a new stake in shares of ASP Isotopes in the 2nd quarter valued at about $272,000. HTLF Bank bought a new stake in shares of ASP Isotopes in the 4th quarter valued at about $141,000. Finally, Rathbones Group PLC bought a new stake in shares of ASP Isotopes in the 4th quarter valued at about $272,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

Insider Buying and Selling at ASP Isotopes

In other ASP Isotopes news, Director Robert John Andrew Ryan purchased 15,596 shares of the stock in a transaction on Monday, January 29th. The shares were purchased at an average price of $2.35 per share, with a total value of $36,650.60. Following the acquisition, the director now directly owns 537,055 shares of the company’s stock, valued at approximately $1,262,079.25. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 26.30% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.